You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


EMA begins review of GSK/Vir’s COVID-19 antibody

The European Medicines Agency (EMA) has launched a review of GlaxoSmithKline (GSK) and Vir Biotechnology’s investigational dual-action monoclonal antibody (mAb) VIR-7831 for the early treatment of COVID-19.